Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2021; 81(4):

Overall Survival with Tafasitamab plus Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Nowakowski, GS; Yoon, DH; Mondello, P; Joffe, E; Peters, A; Fleury, I; Greil, R; Ku, M; Marks, R; Kim, K; Zinzani, PL; Trotman, J; Huang, D; Waltl, EE; Winderlich, M; Ambarkhane, S; Hess, G; Salles, G CL LYMPH MYELOM LEUK. 2021; 21: S392-S393.

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Burgues, JMB; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Costa, PA; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, CR; Salles, G BLOOD. 2021; 138:

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Nowakowski, GS; Yoon, DH; Mondello, P; Joffe, E; Fleury, I; Peters, A; Greil, R; Ku, M; Marks, R; Kim, K; Zinzani, PLL; Trotman, J; Sabatelli, L; Huang, D; Waltl, EE; Winderlich, M; Ambarkhane, S; Kurukulasuriya, NC; Cordoba, R; Hess, G; Salles, G BLOOD. 2021; 138:

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission – a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R BLOOD. 2021; 138:

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Tam, CS; Giannopoulos, K; Jurczak, W; Simkovic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, H; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Brown, JR; Kahl, BS; Ghia, P; Tian, T; Marimpietri, C; Paik, JC; Cohen, A; Huang, J; Robak, T; Hillmen, P BLOOD. 2021; 138:

The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry – a Prospective Cohort Study By the AGMT Study Group

Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Petricevic, B; Leisch, M; Egle, A; Senn, TM; Grochtdreis, T; Greil, R; Stauder, R BLOOD. 2021; 138:

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders – Results from the Aachen Telomeropathy Registry

Beier, F; Tometten, M; Kirschner, M; Halfmeyer, I; Vieri, M; Kricheldorf, K; Maurer, A; Roeth, A; Platzbecker, U; Radsak, MP; Schafhausen, P; Corbacioglu, S; Hoechsmann, B; Wilk, CM; Hinze, C; Chromik, J; Egle, A; Heuser, M; Kreuter, M; Kurth, I; Koschmieder, S; Panse, J; Meyer, R; Isfort, S; Brummendorf, TH BLOOD. 2021; 138:

Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia

Maeding, N; Asslaber, D; Zaborsky, N; Villunger, A; Greil, R; Egle, A BLOOD. 2021; 138:

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Manrique, I; Greil, R; Andel, J; Sormann, S; Hartmann, BL; Podar, K; Egle, A; Petzer, A; Zojer, N; Gunsilius, E; Ruckser, R; Bozic, B; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Schreder, M; Wang, SY; Willenbacher, W; Krauth, MT; Tinchon, C; Fillitz, M; Melchardt, T; Knop, S; Paiva, B; Ludwig, H BLOOD. 2021; 138: